Randomized Trial of Cholesterol Lowering With Evolocumab for Cardiac Allograft Vasculopathy in Heart Transplant Recipients

• DOI: 10.1016/j.jchf.2024.04.026
• Publication Date: 2024-06-26T18:45:33Z
• Authors: Kaspar Broch; Karl B. Lemström; Finn Gustafsson; Hans Eiskjær; Kristjan Karason; Grunde Gjesdal; Morten W. Fagerland; Markku Pentikainen; Jyri Lommi; Einar Gude; Arne K. Andreassen; Tor S. Clemmensen; Evald H. Christia...; Elisabeth Bjørkelund; Erlend S. Berg; Satish Arora; Lars Gullestad
• Keywords: Evolocumab; PCSK9; Clinical endpoint

Cardiac allograft vasculopathy is characterized by increased coronary intimal thickness and a leading cause of death in heart transplant (HTx) recipients despite the routine use statins. The experience with inhibitors proprotein convertase subtilisin-kexin type 9 HTx limited. Our hypothesis was that lowering cholesterol 9inhibitor evolocumab would reduce these patients without compromising safety.